<p>舊金山，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Structure Therapeutics Inc.（納斯達克：GPCR），一家臨牀階段的全球生物製藥公司，專注於開發用於代謝疾病的新型口服小分子治療藥物，特別是肥胖症，今天宣佈其增量承銷公開發行的定價，發行 8,461,538 份美國存托股票（ADS），每份代表三股普通股，公開發行價格為每份 ADS 65.00 美元，並預先融資的認股權證以每份 64.9999 美元的價格購買 1,538,462 份 ADS。所有證券均由 Structure Therapeutics 出售。</p>
<p>預計 Structure Therapeutics 從此次發行中獲得的總收益約為 6.5 億美元，未扣除承銷折扣和佣金及發行費用。此外，Structure Therapeutics 已授予承銷商一個 30 天的選擇權，以公開發行價格購買最多 1,500,000 份額外的 ADS，扣除承銷折扣和佣金。此次發行預計將於 2025 年 12 月 11 日完成，前提是滿足慣例的交割條件。</p>
<p>Jefferies、Leerink Partners、Goldman Sachs &amp; Co. LLC、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 擔任此次發行的聯合賬簿管理人。LifeSci Capital 和 Citizens Capital Markets 擔任此次發行的共同管理人。</p>
<p>此次發行是根據於 2025 年 8 月 6 日向證券交易委員會（SEC）提交的自動貨架註冊聲明（S-3 表格）進行的，包括基礎招股説明書，該註冊聲明在提交時即生效。與此次發行相關的初步招股説明書補充及附帶招股説明書已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上免費獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上免費提供。與此次發行相關的最終招股説明書的副本可在可用時從以下地址獲取：Jefferies LLC，注意：股權承銷招股説明書部，520 Madison Avenue, New York, NY 10022，電話（877）821-7388，或通過電子郵件聯繫 Prospectus_Department@Jefferies.com；Leerink Partners LLC，承銷部，53 State Street, 40th Floor, Boston, MA 02109，電話（800）808-7525 ext. 6105，或通過電子郵件聯繫 syndicate@leerink.com；Goldman Sachs &amp; Co. LLC，注意：招股説明書部，200 West Street, New York, NY 10282，電話（866）471-2526，或通過電子郵件聯繫 prospectus-ny@ny.email.gs.com；Morgan Stanley &amp; Co. LLC，注意：招股説明書部，180 Varick Street, 2nd Floor, New York, NY 10014，電話（866）718-1649，或通過電子郵件聯繫 prospectus@morganstanley.com；Guggenheim Securities, LLC，注意：股權承銷部，330 Madison Avenue, 8th Floor, New York, NY 10017，電話（212）518-9544，或通過電子郵件聯繫 GSEquityProspectusDelivery@guggenheimpartners.com；以及 BMO Capital Markets Corp.，注意：股權承銷部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通過電子郵件聯繫 bmoprospectus@bmo.com。</p>
<p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內出售這些證券的要約、徵求或銷售，除非在任何此類州或司法管轄區的證券法下注冊或合格之前。</p>
<p><strong>關於 Structure Therapeutics</strong></p>
<p>Structure Therapeutics 是一家以科學為驅動的臨牀階段生物製藥公司，專注於發現和開發創新的口服小分子治療藥物，以應對具有重大未滿足醫療需求的慢性代謝疾病。利用其下一代基於結構的藥物發現平台，公司建立了一個強大的 GPCR 靶向管線，擁有多個完全擁有的專有臨牀階段口服小分子化合物，旨在超越傳統生物製劑和肽類療法的可擴展性限制，使更多患者能夠獲得治療。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含 1995 年《私人證券訴訟改革法案》“安全港” 條款所定義的 “前瞻性聲明”。除歷史事實聲明外的所有聲明均可視為前瞻性聲明，包括但不限於有關預期發行時間和完成情況以及預期發行總收益的聲明。此外，當在本新聞稿中使用 “可能”、“可以”、“應該”、“預期”、“相信”、“估計”、“期待”、“打算”、“計劃”、“預測” 等類似表達及其變體時，可能與公司相關的內容也可能被視為前瞻性聲明。前瞻性聲明既不是歷史事實，也不是對未來表現的保證。儘管公司相信這些前瞻性聲明中反映的預期是合理的，但公司無法保證這些預期將被證明是正確的。讀者需注意，實際結果可能與公司前瞻性聲明中表達或暗示的結果存在重大差異，這些差異可能源於多種風險和不確定性，包括但不限於市場風險和不確定性、證券發行的慣常成交條件的滿足以及公司在向美國證券交易委員會（SEC）提交的文件中描述的其他風險和不確定性，包括公司最新的 10-Q 季度報告和公司可能不時向 SEC 提交的未來報告。本新聞稿中包含的所有前瞻性聲明僅在作出聲明的日期有效，並基於管理層在該日期的假設和估計。除法律要求外，公司沒有義務更新這些聲明，以反映作出聲明後發生的事件或存在的情況。</p>
<p><strong>投資者：</strong></p>
<p>Danielle Keatley</p>
<p>Structure Therapeutics Inc.</p>
<p>ir@structuretx.com</p>
<p><strong>媒體：</strong></p>
<p>Dan Budwick</p>
<p>1AB</p>
<p>Dan@1abmedia.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png"/></p>

GPCR

<p>Structure Therapeutics Inc. 宣佈其增大至 6.5 億美元的 ADS 公開發行定價。此次發行包括 8,461,538 份 ADS，每份價格為 65.00 美元，以及 1,538,462 份預先融資的認股權證，每份價格為 64.9999 美元。此次發行預計將於 2025 年 12 月 11 日完成，Jefferies、Leerink Partners、Goldman Sachs、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 將作為聯合賬簿管理人</p>

<p>SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.</p>
<div class="lb-trans"><p>舊金山，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Structure Therapeutics Inc.（納斯達克：GPCR），一家臨牀階段的全球生物製藥公司，專注於開發用於代謝疾病的新型口服小分子治療藥物，特別是肥胖症，今天宣佈其增量承銷公開發行的定價，發行 8,461,538 份美國存托股票（ADS），每份代表三股普通股，公開發行價格為每份 ADS 65.00 美元，並預先融資的認股權證以每份 64.9999 美元的價格購買 1,538,462 份 ADS。所有證券均由 Structure Therapeutics 出售。</p>
</div><p>The gross proceeds to Structure Therapeutics from the offering are expected to be approximately $650 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>預計 Structure Therapeutics 從此次發行中獲得的總收益約為 6.5 億美元，未扣除承銷折扣和佣金及發行費用。此外，Structure Therapeutics 已授予承銷商一個 30 天的選擇權，以公開發行價格購買最多 1,500,000 份額外的 ADS，扣除承銷折扣和佣金。此次發行預計將於 2025 年 12 月 11 日完成，前提是滿足慣例的交割條件。</p>
</div><p>Jefferies, Leerink Partners, Goldman Sachs &amp; Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital and Citizens Capital Markets are acting as co-managers for the offering.</p>
<div class="lb-trans"><p>Jefferies、Leerink Partners、Goldman Sachs &amp; Co. LLC、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 擔任此次發行的聯合賬簿管理人。LifeSci Capital 和 Citizens Capital Markets 擔任此次發行的共同管理人。</p>
</div><p>The offering is being made pursuant to an automatic shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (SEC) on August 6, 2025 and became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available for free on the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.</p>
<div class="lb-trans"><p>此次發行是根據於 2025 年 8 月 6 日向證券交易委員會（SEC）提交的自動貨架註冊聲明（S-3 表格）進行的，包括基礎招股説明書，該註冊聲明在提交時即生效。與此次發行相關的初步招股説明書補充及附帶招股説明書已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上免費獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將提交給 SEC，並將在 SEC 網站 www.sec.gov 上免費提供。與此次發行相關的最終招股説明書的副本可在可用時從以下地址獲取：Jefferies LLC，注意：股權承銷招股説明書部，520 Madison Avenue, New York, NY 10022，電話（877）821-7388，或通過電子郵件聯繫 Prospectus_Department@Jefferies.com；Leerink Partners LLC，承銷部，53 State Street, 40th Floor, Boston, MA 02109，電話（800）808-7525 ext. 6105，或通過電子郵件聯繫 syndicate@leerink.com；Goldman Sachs &amp; Co. LLC，注意：招股説明書部，200 West Street, New York, NY 10282，電話（866）471-2526，或通過電子郵件聯繫 prospectus-ny@ny.email.gs.com；Morgan Stanley &amp; Co. LLC，注意：招股説明書部，180 Varick Street, 2nd Floor, New York, NY 10014，電話（866）718-1649，或通過電子郵件聯繫 prospectus@morganstanley.com；Guggenheim Securities, LLC，注意：股權承銷部，330 Madison Avenue, 8th Floor, New York, NY 10017，電話（212）518-9544，或通過電子郵件聯繫 GSEquityProspectusDelivery@guggenheimpartners.com；以及 BMO Capital Markets Corp.，注意：股權承銷部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通過電子郵件聯繫 bmoprospectus@bmo.com。</p>
</div><p>This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內出售這些證券的要約、徵求或銷售，除非在任何此類州或司法管轄區的證券法下注冊或合格之前。</p>
</div><p><strong>About Structure Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Structure Therapeutics</strong></p>
</div><p>Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.</p>
<div class="lb-trans"><p>Structure Therapeutics 是一家以科學為驅動的臨牀階段生物製藥公司，專注於發現和開發創新的口服小分子治療藥物，以應對具有重大未滿足醫療需求的慢性代謝疾病。利用其下一代基於結構的藥物發現平台，公司建立了一個強大的 GPCR 靶向管線，擁有多個完全擁有的專有臨牀階段口服小分子化合物，旨在超越傳統生物製劑和肽類療法的可擴展性限制，使更多患者能夠獲得治療。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including without limitation, statements concerning the expected timing and completion of the offering and the expected gross proceeds from the offering. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, market risks and uncertainties, the satisfaction of customary closing conditions for an offering of securities and other risk and uncertainties described in the Company’s filings with the SEC, including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿包含 1995 年《私人證券訴訟改革法案》“安全港” 條款所定義的 “前瞻性聲明”。除歷史事實聲明外的所有聲明均可視為前瞻性聲明，包括但不限於有關預期發行時間和完成情況以及預期發行總收益的聲明。此外，當在本新聞稿中使用 “可能”、“可以”、“應該”、“預期”、“相信”、“估計”、“期待”、“打算”、“計劃”、“預測” 等類似表達及其變體時，可能與公司相關的內容也可能被視為前瞻性聲明。前瞻性聲明既不是歷史事實，也不是對未來表現的保證。儘管公司相信這些前瞻性聲明中反映的預期是合理的，但公司無法保證這些預期將被證明是正確的。讀者需注意，實際結果可能與公司前瞻性聲明中表達或暗示的結果存在重大差異，這些差異可能源於多種風險和不確定性，包括但不限於市場風險和不確定性、證券發行的慣常成交條件的滿足以及公司在向美國證券交易委員會（SEC）提交的文件中描述的其他風險和不確定性，包括公司最新的 10-Q 季度報告和公司可能不時向 SEC 提交的未來報告。本新聞稿中包含的所有前瞻性聲明僅在作出聲明的日期有效，並基於管理層在該日期的假設和估計。除法律要求外，公司沒有義務更新這些聲明，以反映作出聲明後發生的事件或存在的情況。</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投資者：</strong></p>
</div><p>Danielle Keatley</p>
<div class="lb-trans"><p>Danielle Keatley</p>
</div><p>Structure Therapeutics Inc.</p>
<div class="lb-trans"><p>Structure Therapeutics Inc.</p>
</div><p>ir@structuretx.com</p>
<div class="lb-trans"><p>ir@structuretx.com</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒體：</strong></p>
</div><p>Dan Budwick</p>
<div class="lb-trans"><p>Dan Budwick</p>
</div><p>1AB</p>
<div class="lb-trans"><p>1AB</p>
</div><p>Dan@1abmedia.com</p>
<div class="lb-trans"><p>Dan@1abmedia.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg3MCM3MzE1MDc1IzIyNDYwMzg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png"/></p>

Structure Therapeutics 宣佈定價擴大至 6.5 億美元的美國存托股票和預先資助認股權證的公開發行 | GPCR 股票新聞